Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (Review)

  • Authors:
    • Björn Georgi
    • Nina Korzeniewski
    • Boris Hadaschik
    • Carsten Grüllich
    • Wilfried Roth
    • Holger Sültmann
    • Sascha Pahernik
    • Markus Hohenfellner
    • Stefan Duensing
  • View Affiliations

  • Published online on: July 28, 2014     https://doi.org/10.3892/ijo.2014.2567
  • Pages: 1337-1344
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Treatment of castration resistant prostate cancer (CRPC) continues to represent a major urooncological challenge due to tumor heterogeneity and the inevitable development of therapy resistance. Although androgen deprivation therapy retains an important role in the management of CRPC, recent evidence suggests that a broader spectrum of therapeutic targets may improve patient response and delay development of advanced disease. Genome-wide analyses have identified four major signaling nodes that are most frequently altered in prostate cancer: i) the androgen receptor (AR); ii) the PI3K pathway; iii) the Ras/Raf/MEK/ERK pathway; and iv) the retinoblastoma protein (pRB) signaling pathway. Extensive crosstalk and redundancy exists between these signaling pathways, which underscores the need for combination therapies. There are several novel AR pathway inhibitors currently in clinical use. Clinical trials are being performed on single-agent PI3K inhibitors with some success in tumors with genetically altered PI3K components. MEK/ERK inhibitors are also in clinical trials and the importance of pRB inactivation in prostate cancer is becoming more widely recognized. A greater understanding of the effects of single agent therapy on compensatory signaling pathway activation that can potentially thwart antitumoral responses is urgently needed and will provide additional insight into the mechanism of therapy resistance and how to further delay the progression to lethal disease.
View Figures
View References

Related Articles

Journal Cover

October 2014
Volume 45 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Georgi, B., Korzeniewski, N., Hadaschik, B., Grüllich, C., Roth, W., Sültmann, H. ... Duensing, S. (2014). Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (Review). International Journal of Oncology, 45, 1337-1344. https://doi.org/10.3892/ijo.2014.2567
MLA
Georgi, B., Korzeniewski, N., Hadaschik, B., Grüllich, C., Roth, W., Sültmann, H., Pahernik, S., Hohenfellner, M., Duensing, S."Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (Review)". International Journal of Oncology 45.4 (2014): 1337-1344.
Chicago
Georgi, B., Korzeniewski, N., Hadaschik, B., Grüllich, C., Roth, W., Sültmann, H., Pahernik, S., Hohenfellner, M., Duensing, S."Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (Review)". International Journal of Oncology 45, no. 4 (2014): 1337-1344. https://doi.org/10.3892/ijo.2014.2567